The effect of short term lithium administration on suppressibility of parathyroid hormone secretion by calcium in vivo

Allen M. Spiegel, M. V. Rudorfer, S. J. Marx, M. Linnoila

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

We performed graded calcium infusions twice in six normal young men, once without medication and a second time after they had received therapeutic doses of lithium carbonate for 5 days. The serum lithium level was 0.73 ± 0.08 meq/liter (mean ± SE) at the beginning of the calcium infusion and reached 0.97 ± 0.13 150 min after receiving a lithium dose (210 min after beginning the test). There was no significant difference in mean basal serum calcium, plasma PTH, or nephrogenous cAMP for the untreated and treated periods. There was also no significant difference in calcium suppressibility of PTH secretion, as reflected by changes in nephrogenous cAMP. Changes in plasma PTH in response to calcium infusion likewise did not differ for the two periods, with the exception of a slightly greater degree of suppression in the unmediated state (77% vs. 57% on lithium: P < 0.02, by paired t test) at the last time point of the calcium infusion. The data show that short term administration of therapeutic doses of lithium does not alter the set-point for calcium suppression of PTH secretion in man. Further studies of calcium suppressibility of PTH secretion in subjects receiving long term lithium therapy will be needed to evaluate the pathophysiology of lithium-induced hypercalcemia.

Original languageEnglish (US)
Pages (from-to)354-357
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume59
Issue number2
StatePublished - 1984
Externally publishedYes

Fingerprint

Parathyroid Hormone
Lithium
Calcium
Lithium Carbonate
Plasmas
Hypercalcemia
Serum
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

The effect of short term lithium administration on suppressibility of parathyroid hormone secretion by calcium in vivo. / Spiegel, Allen M.; Rudorfer, M. V.; Marx, S. J.; Linnoila, M.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 59, No. 2, 1984, p. 354-357.

Research output: Contribution to journalArticle

@article{66091d4afc514e6a8cb5619f58e3d8bd,
title = "The effect of short term lithium administration on suppressibility of parathyroid hormone secretion by calcium in vivo",
abstract = "We performed graded calcium infusions twice in six normal young men, once without medication and a second time after they had received therapeutic doses of lithium carbonate for 5 days. The serum lithium level was 0.73 ± 0.08 meq/liter (mean ± SE) at the beginning of the calcium infusion and reached 0.97 ± 0.13 150 min after receiving a lithium dose (210 min after beginning the test). There was no significant difference in mean basal serum calcium, plasma PTH, or nephrogenous cAMP for the untreated and treated periods. There was also no significant difference in calcium suppressibility of PTH secretion, as reflected by changes in nephrogenous cAMP. Changes in plasma PTH in response to calcium infusion likewise did not differ for the two periods, with the exception of a slightly greater degree of suppression in the unmediated state (77{\%} vs. 57{\%} on lithium: P < 0.02, by paired t test) at the last time point of the calcium infusion. The data show that short term administration of therapeutic doses of lithium does not alter the set-point for calcium suppression of PTH secretion in man. Further studies of calcium suppressibility of PTH secretion in subjects receiving long term lithium therapy will be needed to evaluate the pathophysiology of lithium-induced hypercalcemia.",
author = "Spiegel, {Allen M.} and Rudorfer, {M. V.} and Marx, {S. J.} and M. Linnoila",
year = "1984",
language = "English (US)",
volume = "59",
pages = "354--357",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - The effect of short term lithium administration on suppressibility of parathyroid hormone secretion by calcium in vivo

AU - Spiegel, Allen M.

AU - Rudorfer, M. V.

AU - Marx, S. J.

AU - Linnoila, M.

PY - 1984

Y1 - 1984

N2 - We performed graded calcium infusions twice in six normal young men, once without medication and a second time after they had received therapeutic doses of lithium carbonate for 5 days. The serum lithium level was 0.73 ± 0.08 meq/liter (mean ± SE) at the beginning of the calcium infusion and reached 0.97 ± 0.13 150 min after receiving a lithium dose (210 min after beginning the test). There was no significant difference in mean basal serum calcium, plasma PTH, or nephrogenous cAMP for the untreated and treated periods. There was also no significant difference in calcium suppressibility of PTH secretion, as reflected by changes in nephrogenous cAMP. Changes in plasma PTH in response to calcium infusion likewise did not differ for the two periods, with the exception of a slightly greater degree of suppression in the unmediated state (77% vs. 57% on lithium: P < 0.02, by paired t test) at the last time point of the calcium infusion. The data show that short term administration of therapeutic doses of lithium does not alter the set-point for calcium suppression of PTH secretion in man. Further studies of calcium suppressibility of PTH secretion in subjects receiving long term lithium therapy will be needed to evaluate the pathophysiology of lithium-induced hypercalcemia.

AB - We performed graded calcium infusions twice in six normal young men, once without medication and a second time after they had received therapeutic doses of lithium carbonate for 5 days. The serum lithium level was 0.73 ± 0.08 meq/liter (mean ± SE) at the beginning of the calcium infusion and reached 0.97 ± 0.13 150 min after receiving a lithium dose (210 min after beginning the test). There was no significant difference in mean basal serum calcium, plasma PTH, or nephrogenous cAMP for the untreated and treated periods. There was also no significant difference in calcium suppressibility of PTH secretion, as reflected by changes in nephrogenous cAMP. Changes in plasma PTH in response to calcium infusion likewise did not differ for the two periods, with the exception of a slightly greater degree of suppression in the unmediated state (77% vs. 57% on lithium: P < 0.02, by paired t test) at the last time point of the calcium infusion. The data show that short term administration of therapeutic doses of lithium does not alter the set-point for calcium suppression of PTH secretion in man. Further studies of calcium suppressibility of PTH secretion in subjects receiving long term lithium therapy will be needed to evaluate the pathophysiology of lithium-induced hypercalcemia.

UR - http://www.scopus.com/inward/record.url?scp=0021233396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021233396&partnerID=8YFLogxK

M3 - Article

C2 - 6330156

AN - SCOPUS:0021233396

VL - 59

SP - 354

EP - 357

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -